- Previous Close
2.7940 - Open
2.7160 - Bid 2.9140 x --
- Ask 3.0900 x --
- Day's Range
2.6000 - 3.1700 - 52 Week Range
2.4780 - 4.9900 - Volume
6,702 - Avg. Volume
2,455 - Market Cap (intraday)
210.678M - Beta (5Y Monthly) 2.78
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1200 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing. The Biosciences segment provides instruments that enable the handling of cells and rare samples, and rapid transfer of liquids and reagents, as well as downstream analysis platforms. The Bioautomation segment offers end-to-end products and services in precision dispensing, advanced sample preparation, multiplex analysis and assay miniaturization, diagnostic and medical device manufacturing for life science and diagnostic industries. It primarily serves medical, pharmaceutical, and cosmetic industries. The company offers its products through sales organizations, as well as through an extensive distributor network. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was incorporated in 2016 and is headquartered in Gothenburg, Sweden.
www.bico.comRecent News: 49Z.F
View MorePerformance Overview: 49Z.F
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 49Z.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 49Z.F
View MoreValuation Measures
Market Cap
186.16M
Enterprise Value
293.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.24
Price/Book (mrq)
0.78
Enterprise Value/Revenue
1.63
Enterprise Value/EBITDA
6.29
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.28%
Return on Assets (ttm)
-3.08%
Return on Equity (ttm)
-3.07%
Revenue (ttm)
1.95B
Net Income Avi to Common (ttm)
-90.1M
Diluted EPS (ttm)
-0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
946.3M
Total Debt/Equity (mrq)
58.63%
Levered Free Cash Flow (ttm)
49.2M